
AlmostPerfect
Iron
- Joined
- Sep 30, 2020
- Posts
- 76
- Reputation
- 61
I think PF-00277343, which is a selective thyroid hormone receptor β (TRβ) agonist for hair growth, would mog hard for eyebrow and eyelash growth without the potential negative effects on collagen from minoxidil and Bimatoprost which can cause:
I am going to get a small amount made to test so If anyone would like to get a portion of it to try as well DM me. The topical dose is very small.
Here is an AI summary of PF:
PF-00277343 is an experimental compound developed by Pfizer as a topical treatment for hair growth, particularly targeting androgenetic alopecia (pattern hair loss). It functions as a selective thyroid hormone receptor β (TRβ) agonist, stimulating hair follicle activity without the vascular side effects associated with treatments like minoxidil
Key Facts about PF-00277343:
PF-00277343 represents a novel approach to hair growth stimulation, particularly for sensitive areas like eyebrows and eyelashes. Its distinct mechanism and favorable safety profile make it a compelling alternative to existing treatments.
- Periorbital fat loss: Documented side effect where repeated application leads to sunken eyes or hollowing around the orbital region. This is known as deepening of the upper eyelid sulcus (DUES).
- Hyperpigmentation: Causes darkening of the skin where applied (sometimes permanent).
- Irritation and redness: Chronic low-level inflammation can occur with use.
- Skin thinning in some users (anecdotal but observed by dermatologists).
I am going to get a small amount made to test so If anyone would like to get a portion of it to try as well DM me. The topical dose is very small.
Here is an AI summary of PF:
PF-00277343 is an experimental compound developed by Pfizer as a topical treatment for hair growth, particularly targeting androgenetic alopecia (pattern hair loss). It functions as a selective thyroid hormone receptor β (TRβ) agonist, stimulating hair follicle activity without the vascular side effects associated with treatments like minoxidil
Key Facts about PF-00277343:
- Mechanism of Action: PF-00277343 selectively activates TRβ receptors, promoting hair growth by stimulating dermal papilla cells and enhancing hair follicle proliferation. This mechanism is distinct from minoxidil, which primarily acts as a vasodilator.
- Efficacy: In preclinical studies, PF-00277343 demonstrated significant hair growth stimulation. For instance, in the C3H/HeN mouse model, topical application of PF-00277343 at a concentration of 0.003% induced hair growth, representing a 3000-fold increase in efficacy compared to minoxidil, which requires 2.5–5.0% concentration for similar effects. Academia
- Safety Profile: PF-00277343 is designed for topical use with minimal systemic absorption, reducing the risk of systemic side effects. It is rapidly metabolized, limiting systemic exposure. Additionally, it does not inhibit collagen synthesis, avoiding potential skin aging effects associated with minoxidil.Academia
- Application Potential: Given its targeted action and safety profile, PF-00277343 is a promising candidate for promoting eyebrow and eyelash growth without the adverse effects linked to other treatments.
- Minoxidil: A vasodilator that promotes hair growth by widening blood vessels, increasing blood flow to hair follicles. However, it may inhibit collagen synthesis, potentially leading to skin aging and other side effects. PubMed
- PF-00277343: Stimulates hair growth through TRβ receptor activation without affecting vascular function or collagen synthesis, offering a potentially safer alternative for facial hair applications.
PF-00277343 represents a novel approach to hair growth stimulation, particularly for sensitive areas like eyebrows and eyelashes. Its distinct mechanism and favorable safety profile make it a compelling alternative to existing treatments.